Rational Application of Macrophage-specific LXR Agonists Avoids the Pitfalls of SREBP-induced Lipogenesis

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2018 May 2

PMID 29712848

Citations 8

Authors

Jason A Magida

Ronald M Evans

Affiliations

Soon will be listed here.

Citing Articles

Future therapeutic perspectives in nonalcoholic fatty liver disease: a focus on nuclear receptors, a promising therapeutic target.

Stan S, Biciusca V, Clenciu D, Mitrea A, Boldeanu M, Durand P Med Pharm Rep. 2024; 97(2):111-119.

PMID: 38746033 PMC: 11090283. DOI: 10.15386/mpr-2628.

International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.

Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A Pharmacol Rev. 2023; 75(6):1233-1318.

PMID: 37586884 PMC: 10595025. DOI: 10.1124/pharmrev.121.000436.

Macrophage Paired Immunoglobulin-Like Receptor B Deficiency Promotes Peripheral Atherosclerosis in Apolipoprotein E-Deficient Mice.

Su W, Liang L, Zhou L, Cao Y, Zhou X, Liu S Front Cell Dev Biol. 2022; 9:783954.

PMID: 35321392 PMC: 8936951. DOI: 10.3389/fcell.2021.783954.

Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease.

Kotlyarov S, Bulgakov A Cells. 2021; 10(11).

PMID: 34831201 PMC: 8616072. DOI: 10.3390/cells10112978.

Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis.

Feng K, Ma C, Liu Y, Yang X, Yang Z, Chen Y Theranostics. 2021; 11(6):2634-2654.

PMID: 33456564 PMC: 7806465. DOI: 10.7150/thno.53139.

References

Kirchgessner T, Sleph P, Ostrowski J, Lupisella J, Ryan C, Liu X . Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils. Cell Metab. 2016; 24(2):223-33. DOI: 10.1016/j.cmet.2016.07.016. View

Pfeifer T, Buchebner M, Chandak P, Patankar J, Kratzer A, Obrowsky S . Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr Pharm Biotechnol. 2010; 12(2):285-92. PMC: 3163291. DOI: 10.2174/138920111794295774. View

Chawla A, Boisvert W, Lee C, Laffitte B, Barak Y, Joseph S . A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001; 7(1):161-71. DOI: 10.1016/s1097-2765(01)00164-2. View

A-Gonzalez N, Castrillo A . Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. Biochim Biophys Acta. 2011; 1812(8):982-94. DOI: 10.1016/j.bbadis.2010.12.015. View

Muse E, Yu S, Edillor C, Tao J, Spann N, Troutman T . Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages. Proc Natl Acad Sci U S A. 2018; 115(20):E4680-E4689. PMC: 5960280. DOI: 10.1073/pnas.1714518115. View

Grefhorst A, Elzinga B, Voshol P, Plosch T, Kok T, Bloks V . Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem. 2002; 277(37):34182-90. DOI: 10.1074/jbc.M204887200. View

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray K, Thompson A . Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302(18):1993-2000. PMC: 3284229. DOI: 10.1001/jama.2009.1619. View

Joseph S, Castrillo A, Laffitte B, Mangelsdorf D, Tontonoz P . Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003; 9(2):213-9. DOI: 10.1038/nm820. View

Spann N, Garmire L, McDonald J, Myers D, Milne S, Shibata N . Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell. 2012; 151(1):138-52. PMC: 3464914. DOI: 10.1016/j.cell.2012.06.054. View

10.

Benjamin E, Blaha M, Chiuve S, Cushman M, Das S, Deo R . Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017; 135(10):e146-e603. PMC: 5408160. DOI: 10.1161/CIR.0000000000000485. View